-
2023-506996-89-00
5
2024-06-13
Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-507751-30-00
9
2024-05-27
relapsed or refractory multiple myeloma
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2022-503090-11-00
4
2024-05-23
Hodgkin lymphoma
-
2023-509071-16-00
6
2024-05-22
Septic shock
-
2023-508818-42-00
10
2024-05-21
Generalized Epidermolysis Bullosa Simplex (EBS)
-
2023-507677-18-00
9
2024-05-17
Chronic Myeloid Leukemia
-
2023-504600-28-00
10
2024-05-09
Metastatic Hepatocellular Carcinoma (HCC)
-
2022-502276-23-00
5
2024-04-25
JAK2V617F-positive high-risk Polycythemia Vera
-
2023-507073-18-00
4
2024-04-24
Cirrhosis
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504374-38-00
5
2024-04-12
Locally advanced cervical cancer
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-505221-14-00
4
2024-04-04
Multiple Myeloma
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-504756-96-00
5
2024-03-22
Recurrent pericarditis, idiopathic or secondary to invasive cardiac pr
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2024-512658-41-00
10
2024-03-06
Congestive Heart Failure
-
2023-504735-41-00
5
2024-03-05
Moderately to Severely Active Crohn's Disease
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus